Affiliation:
1. Veltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery, Pirogov Russian National Research Medical University
2. Chita State Medical Academy
Abstract
Recurrent episodes of bronchial obstruction in preschool children are one of the important risk factors for the development of bronchial asthma.Purpose. The study aimed at investigating the clinical and immunological characteristics of children with acute bronchitis and to determine the clinical effectiveness of course anti-inflammatory therapy.Material and methods. The study was a single-center prospective cohort, including 1–5-year-old patients with acute bronchitis (main group, n = 109): a group with acute simple bronchitis (n = 34) and acute obstructive bronchitis (n = 75). Reference group: children of health group 2 (n = 29). Clinical and anamnestic and laboratory methods were used. Patients with a positive API (Asthma Predictive Index) were administered montelukast at a dose of 4 mg orally once a day for 3 months (control points at 1 and 3 months), reference patients received symptomatic therapy for respiratory infection. The end point of the study is the absence of bronchial obstruction. The effectiveness of the use of Montelukast was evaluated by calculating the clinical index, efficiency coefficient. Results. A statistically significant predominance of intoxication symptoms was found in patients with acute simple bronchitis (p = 0.02), signs of respiratory failure (p < 0.001), and peripheral eosinophilia — in children with acute obstructive bronchitis (p = 0.02). In etiology, rhinovirus significantly prevailed in patients with bronchial obstruction, and RS virus prevailed in patients with acute simple bronchitis (p = 0.02). The cytokine profile of patients with acute obstructive bronchitis is characterized by a decrease in the levels of macrophage inflammatory proteins (p = 0.01) and IL-8 (p = 0.048). A prolonged course of montelukast in children with a positive API significantly reduces the severity of subsequent acute respiratory infections, reduces the frequency of bronchial obstruction and the risk of bronchial asthma (p < 0.001).Conclusion. Evaluation of the results of montelukast therapy demonstrated clinical efficacy in patients with a positive API index.
Publisher
The National Academy of Pediatric Science and Innovation
Subject
Pediatrics, Perinatology and Child Health
Reference25 articles.
1. Geppe N.A., Ivanova N.A., Kamaev A.V., Kolosova N.G., Kondyurina E.G., Malakhov A.B. et al. Bronchial obstruction on the background of acute respiratory infection in preschool children: diagnosis, differential diagnosis, therapy, prevention. Moscow: MedKom-Pro, 2019; 80. (in Russ.)
2. Tsarev S.V. Virus-induced bronchial asthma: features of the course and therapeutic tactics. Ehffektivnaya farmakoterapiya 2015; 20(1): 26–30. (in Russ.)
3. Meissner H.C. Viral Bronchiolitis in Children. N Engl J Med 2016; 374(1): 62–72. DOI: 10.1056/NEJMra1413456
4. Piedra F.A., Mei M., Avadhanula V., Mehta R., Aideyan L., Garofalo R.P. et al. The interdependencies of viral load, the innate immune response, and clinical outcome in children presenting to the emergency department with respiratory syncytial virus-associated bronchiolitis. PLoS One 2017; 12(3): e0172953. DOI: 10.1371/journal.pone.0172953
5. Mizernitskiy Yu.L. Pathogenetic rationale for the use of montelukast (Singlon) in acute respiratory viral infections with broncho-obstructive syndrome in children of early and preschool age. Rossiyskiy Vestnik Perinatologii i Pediatrii 2020; 65(6): 129–132. (in Russ.) DOI: 10.21508/1027–4065–2020–65–6–129–132